Difference between revisions of "Team:Sydney Australia/Applied Design"

Line 165: Line 165:
 
#please h4 {
 
#please h4 {
 
   font-family: 'Quicksand', sans-serif;
 
   font-family: 'Quicksand', sans-serif;
−
color: #3e3f3f;
+
  color: #3e3f3f;
 
   font-size: 16px;
 
   font-size: 16px;
 
   LINE-HEIGHT:20px;
 
   LINE-HEIGHT:20px;
Line 378: Line 378:
 
#small9 {border: 5px solid #468e68;}
 
#small9 {border: 5px solid #468e68;}
 
#info {border: 5px solid #f6daa3;}
 
#info {border: 5px solid #f6daa3;}
 +
 +
#preloader {
 +
position: relative;
 +
width: 100%;
 +
height: 100%;
 +
background: white;
 +
}
 +
 +
#discoveryChart {
 +
position: relative;
 +
width: 620px;
 +
height: 240px;
 +
margin: auto;
 +
top: 0;
 +
left: 0;
 +
right: 0;
 +
bottom: 0;
 +
}
 +
 +
#pieContainer {
 +
position: absolute;
 +
width: 240px;
 +
height: 240px;
 +
left: 0;
 +
overflow: visible;
 +
}
 +
 +
#discoveryTextContainer {
 +
position: relative;
 +
width: 380px;
 +
height: 240px;
 +
left: 260px;
 +
}
 +
 +
#lines {
 +
position: relative;
 +
margin: auto;
 +
top: 0;
 +
left: 0;
 +
right: 0;
 +
bottom: 0;
 +
}
 +
 +
#line1,
 +
#line2,
 +
#line3,
 +
#line4 {
 +
fill:none;
 +
stroke-width:1;
 +
stroke-miterlimit:10;
 +
stroke-dasharray: 50;
 +
  stroke-dashoffset: -50;
 +
}
 +
 +
#line1{
 +
stroke:#BCCF00;
 +
}
 +
#line2{
 +
stroke:#F6A000;
 +
}
 +
#line3{
 +
stroke:#009FE3;
 +
}
 +
#line4{
 +
stroke:#E84E0F;
 +
}
 +
 +
#chart {
 +
position: absolute;
 +
overflow: visible;
 +
}
 +
 +
#green {
 +
fill:#BCCF00;
 +
}
 +
 +
#orange {
 +
fill:#F6A000;
 +
}
 +
 +
#blue {
 +
fill:#009FE3;
 +
}
 +
 +
#red {
 +
fill:#E84E0F;
 +
}
 +
 +
#leftBar {
 +
display: inline-block;
 +
background-color: #E84E0F;
 +
width: 6px;
 +
height: 100%;
 +
}
 +
 +
.title {
 +
width: 100%;
 +
}
 +
 +
#discoveryTextContainer {
 +
border-left: 0px solid #EEE;
 +
}
 +
 +
.title h2 {
 +
position: absolute;
 +
font-family: 'Quicksand';
 +
text-transform: uppercase;
 +
font-size: 28px;
 +
margin-top: 14px;
 +
left: 20px;
 +
visibility: hidden;
 +
}
 +
 +
.title p {
 +
position: absolute;
 +
font-family: 'Quicksand', sans-serif;
 +
margin-left: 20px;
 +
top: 48px;
 +
visibility: hidden;
 +
}
  
 
</style>
 
</style>
Line 407: Line 527:
  
  
−
{{:Team:Sydney_Australia/templates/barriers}}
+
<div class="row">
 +
  <div class = "content" id = "please">
 +
  <div id="discoveryChart">
 +
 
 +
<div id="pieContainer">
 +
 +
<svg id="chart" x="0px" y="0px" width="239.3px" height="239px" viewBox="0 0 239.3 239">
 +
<path id="orange" d="M119.5,58c29.5,0,54.2,20.7,60.2,48.4l56.9-12.1C225,40.4,176.9,0,119.5,0c-0.1,0,0.5,0-0.5,0v58.1
 +
C120,58.1,119.4,58,119.5,58z"/>
 +
<path id="green" d="M58,119.5c0-33.9,28-61.3,61-61.5V0C54,0.1,0,53.6,0,119.5c0,29.1,10.6,55.9,27.9,76.6l44.4-37.3
 +
C63.4,148.1,58,134.4,58,119.5z"/>
 +
<path id="red" d="M179.8,106.5c0.9,4.2,1.4,8.6,1.4,13c0,24.3-14.1,45.3-34.6,55.3l25.5,52.2c39.8-19.4,67.2-60.2,67.2-107.5
 +
c0-8.6-0.9-17-2.7-25.1L179.8,106.5z"/>
 +
<path id="blue" d="M119.8,181c-19,0-36-8.6-47.3-22.2L28,196.1c21.9,26.2,54.9,42.9,91.7,42.9c18.8,0,36.5-4.3,52.3-12
 +
l-25.5-52.2C138.5,178.8,129.4,181,119.8,181z"/>
 +
</svg>
 +
 
 +
 +
<svg id="lines" width="69.1px" height="69.1px" viewBox="0 0 69.1 69.1">
 +
<line id="line1" x1="34.5" y1="34.5" x2="0.7" y2="0.7"/>
 +
<line id="line2" x1="34.5" y1="34.5" x2="68.4" y2="0.7"/>
 +
<line id="line3" x1="34.5" y1="34.5" x2="0.7" y2="68.4"/>
 +
<line id="line4" x1="34.5" y1="34.5" x2="68.4" y2="68.4"/>
 +
</svg>
 +
</div><!--end pie container-->
 +
 
 +
<div id="discoveryTextContainer">
 +
<div id="description" class="title">
 +
<h2>Barriers to Entry</h2>
 +
<p>Click on the Segments in the Pie Chart to learn about the barriers to enter the insulin market.</p>
 +
</div>
 +
<div id="titleOne" class="title">
 +
<h2>Technical Barriers</h2>
 +
<p>In the current manufacturing world, recombinant methods are seen as difficult and time intensive. As a result of this, many avoid using recombinant technologies for therapeutic production regimes. 
 +
</p>
 +
</div>
 +
<div id="titleTwo" class="title">
 +
<h2>Legal Barriers</h2>
 +
<p>It took our iGEM team a full couple of months before we were comfortable to say that we had a new insulin to add to the market. We were also able to utilize expertise to navigate through the legal sphere, which greatly aided our process. In general though, due to the number of analogue insulins under patent, its very difficult to ‘create’ a new insulin.
 +
</p>
 +
</div>
 +
<div id="titleThree" class="title">
 +
<h2>Market Barriers</h2>
 +
<p>Every 5 years, the Australian governments Pharmaceutical Benefits Scheme undergoes negotiation with the respective manufacturing plants and suppliers to discuss price points for that period. <br>
 +
This system ultimately favours highly established, elite market players with the market scale to supply an entire region.
 +
</p>
 +
</div>
 +
<div id="titleFour" class="title">
 +
<h2>Cost Barriers</h2>
 +
<p>When people say ‘nothing comes cheap,’ they’re really talking about drug development. To say its expensive really undermines the meaning of expensive. Clinical trials generally cost around US$1 Billion to start with. Production plants for insulin manufacturing can fall anywhere between US$100-$500M, and then a license can cost up to another US$100M. Understandably, these costs limit majority of the wishful market entrants.
 +
</p>
 +
</div>
 +
</div>
 +
<div id="preloader"></div>
 +
</div>
 +
</div>
 +
</div>
 +
 
 +
<script src='https://cdnjs.cloudflare.com/ajax/libs/gsap/1.19.0/TweenMax.min.js'></script>
 +
    <script>
 +
var firstMove = true;
 +
var active;
 +
var tl;
 +
 
 +
var g = document.getElementById('green');
 +
var o = document.getElementById('orange');
 +
var b = document.getElementById('blue');
 +
var r = document.getElementById('red');
 +
 
 +
var dc = document.getElementById('discoveryChart');
 +
 
 +
function setup() {
 +
TweenMax.set('#chart', {scale: 0});
 +
TweenMax.set('#lines', {scale: 1.5 });
 +
TweenMax.set(['#description h2', '#titleOne h2','#titleTwo h2','#titleThree h2','#titleFour h2'], { x: '-=8' });
 +
TweenMax.to('#preloader', 0.25, { autoAlpha: 0 });
 +
animate();
 +
listeners();
 +
};
 +
 
 +
function animate() {
 +
TweenMax.to(['#line1','#line2','#line3','#line4'], 1.25, { strokeDashoffset: 50, ease: Power3.easeInOut });
 +
TweenMax.to('#chart', 1.5, { scale: 1, ease: Power3.easeOut, delay: .84 });
 +
TweenMax.to(['#description h2', '#description p'], 1.5, { x: 0, autoAlpha: 1, ease: Power3.easeOut });
 +
 +
tl = new TimelineMax();
 +
};
 +
 
 +
function listeners() {
 +
 +
g.addEventListener('click', highlightGreen);
 +
 +
o.addEventListener('click', highlightOrange);
 +
 +
b.addEventListener('click', highlightBlue);
 +
 +
r.addEventListener('click', highlightRed);
 +
 
 +
};
 +
 
 +
function removeDescription() {
 +
TweenMax.to(['#description h2', '#description p'], 1, { autoAlpha: 0, ease: Linear.easeNone });
 +
};
 +
 
 +
function highlightGreen() {
 +
 
 +
removeDescription();
 +
 +
if (active === 'orange') {
 +
placeOrange();
 +
} else if (active === 'blue') {
 +
placeBlue();
 +
} else if (active === 'red') {
 +
placeRed();
 +
}
 +
 +
active = 'green';
 +
 +
tl.to('#green', .5, { x: -10, y: -10, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #BCCF00', ease: Linear.easeNone });
 +
tl.to('#titleOne h2', .5, { x: 0, autoAlpha: 1, ease: Linear.easeNone }, '-=0.25');
 +
tl.to('#titleOne p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5');
 +
 +
};
 +
function placeGreen() {
 +
tl.to('#green', .5, { x: 0, y: 0, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone });
 +
tl.to('#titleOne h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5');
 +
tl.to('#titleOne p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5');
 +
};
 +
 
 +
function highlightOrange() {
 +
 +
removeDescription();
 +
 +
if (active === 'blue') {
 +
placeBlue();
 +
} else if (active === 'green') {
 +
placeGreen();
 +
} else if (active === 'red') {
 +
placeRed();
 +
}
 +
 +
active = 'orange';
 +
 +
tl.to('#orange', .5, { x: 8, y: -10, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #F6A000', ease: Linear.easeNone });
 +
tl.to('#titleTwo h2', .5, { x: '0', autoAlpha: 1, ease: Linear.easeNone }, '-=0.25');
 +
tl.to('#titleTwo p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5');
 +
};
 +
function placeOrange() {
 +
tl.to('#orange', .5, { x: 0, y: 0, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone });
 +
tl.to('#titleTwo h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5');
 +
tl.to('#titleTwo p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5');
 +
};
 +
 
 +
function highlightBlue() {
 +
 +
removeDescription();
 +
 +
if (active === 'green') {
 +
placeGreen();
 +
} else if (active === 'orange') {
 +
placeOrange();
 +
} else if (active === 'red') {
 +
placeRed();
 +
}
 +
 +
active = 'blue';
 +
 +
tl.to('#blue', .5, { x: -2, y: 12, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #009FE3', ease: Linear.easeNone });
 +
tl.to('#titleThree h2', .5, { x: '0', autoAlpha: 1, ease: Linear.easeNone }, '-=0.25');
 +
tl.to('#titleThree p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5');
 +
};
 +
function placeBlue() {
 +
tl.to('#blue', .5, { x: 0, y: 0, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone });
 +
tl.to('#titleThree h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5');
 +
tl.to('#titleThree p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5');
 +
};
 +
 
 +
function highlightRed() {
 +
 +
removeDescription();
 +
 +
if (active === 'orange') {
 +
placeOrange();
 +
} else if (active === 'blue') {
 +
placeBlue();
 +
} else if (active === 'green') {
 +
placeGreen();
 +
}
 +
 +
active = 'red';
 +
 +
tl.to('#red', .5, { x: 10, y: 4, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '6px solid #E84E0F', ease: Linear.easeNone });
 +
tl.to('#titleFour h2', .5, { x: '0', autoAlpha: 1, ease: Linear.easeNone }, '-=0.25');
 +
tl.to('#titleFour p', .5, { autoAlpha: 1, ease: Linear.easeNone }, '-=.5');
 +
};
 +
function placeRed() {
 +
 +
tl.to('#red', .5, { x: 0, y: 0, ease: Power3.easeOut });
 +
tl.to('#discoveryTextContainer', .5, { borderLeft: '0px solid #EEE', ease: Linear.easeNone });
 +
tl.to('#titleFour h2', .5, { x: '-=8', autoAlpha: 0, ease: Linear.easeNone }, '-=0.5');
 +
tl.to('#titleFour p', .5, { autoAlpha: 0, ease: Linear.easeNone }, '-=.5');
 +
 
 +
};
 +
 
 +
document.addEventListener("DOMContentLoaded", setup);</script>
  
  

Revision as of 00:40, 29 October 2017

The Issue

The price of insulin is too high for many across the globe. For type I diabetics, who must take insulin every day to survive, and roughly 30% of type II diabetics, this issue constrains their quality of life. Worse still, diagnosis of diabetes is on the rise.
Currently 92% of the insulin market is produced by 3 pharmaceutical companies. In economics, this kind of market share is called an oligopoly. In these kinds of markets, generic or biosimilar insulins have a hard time breaking through, simply due to the enormity of market share that the other three own.
To make things just a little more difficult, clinical trial expenses and regulatory licensing means that very few small to medium sized manufacturing plants can enter the market. Because of these constraints, the insulin market is spiraled out, and as such, is largely unaffordable and inaccessible across the board.

Barriers to Entry

Click on the Segments in the Pie Chart to learn about the barriers to enter the insulin market.

Technical Barriers

In the current manufacturing world, recombinant methods are seen as difficult and time intensive. As a result of this, many avoid using recombinant technologies for therapeutic production regimes.

Legal Barriers

It took our iGEM team a full couple of months before we were comfortable to say that we had a new insulin to add to the market. We were also able to utilize expertise to navigate through the legal sphere, which greatly aided our process. In general though, due to the number of analogue insulins under patent, its very difficult to ‘create’ a new insulin.

Market Barriers

Every 5 years, the Australian governments Pharmaceutical Benefits Scheme undergoes negotiation with the respective manufacturing plants and suppliers to discuss price points for that period.
This system ultimately favours highly established, elite market players with the market scale to supply an entire region.

Cost Barriers

When people say ‘nothing comes cheap,’ they’re really talking about drug development. To say its expensive really undermines the meaning of expensive. Clinical trials generally cost around US$1 Billion to start with. Production plants for insulin manufacturing can fall anywhere between US$100-$500M, and then a license can cost up to another US$100M. Understandably, these costs limit majority of the wishful market entrants.

Potential Solutions



1. PUBLIC TRADING SCHEME
2. OPEN-SOURCE INSULIN PUMP
3. STANDARD BUSINESS MODEL
4. PRIVATE INVESTMENT
5. BATHTUB INSULIN
6. PUBLIC INVESTMENT
7. GENE THERAPY
8. GUT BACTERIA INSULIN
9. ANIMAL
INSULIN
10.BLACK MARKET
INSULIN

Find out More Info About these Solutions By Clicking on Their Box!

1. Public Trading Scheme

BACKGROUND


ISSUES







stuff

2. Open-Source Insulin Pump / Cloud Monitoring

3. Standart Business Model

4. Private Investment

5. Bathtub Insulin

6. Public Investment

7. Gene Therapy

8. Gut Bacteria Insulin Secretion

9. Animal Insulin

10. Black Market Insulin

Our Solution

Making Biosynthetic Bacteria Open Source!